

Juan Luis Tamargo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214098/publications.pdf>

Version: 2024-02-01

332
papers

80,693
citations

8159

76
h-index

407

277
g-index

373
all docs

373
docs citations

373
times ranked

60085
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
3	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
4	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
5	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
6	2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal, 2015, 36, 3075-3128.	1.0	3,902
7	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal, 2014, 35, 2873-2926.	1.0	3,549
8	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
9	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
10	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
11	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	1.0	2,305
12	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	1.0	2,176
13	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
14	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	1.0	1,996
15	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
16	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	1.0	1,396
17	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	1.2	1,280
18	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	1.0	1,253

#	ARTICLE	IF	CITATIONS
19	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 27, 1341-1381.	1.0	1,192
20	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
21	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€”Executive Summary. <i>Journal of the American College of Cardiology</i> , 2006, 48, 854-906.	1.2	1,044
22	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2006, 114, e385-484.	1.6	1,031
23	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
24	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, e101-e198.	1.2	756
25	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
26	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, e269-367.	1.6	747
27	Editor's Choice â€” 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 305-368.	0.8	734
28	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Group) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38</i>	0.7	661
29	Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Europace</i> , 2006, 8, 651-745. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) <i>Tj ETQq1 1 0.784314 rgBT /Ov</i>	1.6	618
30	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationâ€”executive summary. <i>European Heart Journal</i> , 2006, 27, 1979-2030.	1.0	612
31	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) <i>Tj ETQq1 1 0.784314 rgBT /Ov</i>	0.7	546
32	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
33	Expert consensus document on ?adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.	1.0	465
34	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathâ€”executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.0	454
35	with the European Heart Rhythm Associat. <i>European Heart Journal</i> , 2006, 27, 2099-2140. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) <i>Tj ETQq1 1 0.784314 rgBT /O</i>	1.6	400
36	Pharmacology of cardiac potassium channels. <i>Cardiovascular Research</i> , 2004, 62, 9-33.	1.8	398

#	ARTICLE	IF	CITATIONS
37	Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. <i>British Journal of Pharmacology</i> , 2001, 133, 117-124.	2.7	381
38	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2006, 48, e149-e246.	1.2	312
39	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. <i>Circulation</i> , 2006, 114, 700-752.	1.6	294
40	Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. <i>General Pharmacology</i> , 1993, 24, 857-862.	0.7	265
41	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating 2006 ACCF/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation). <i>Circulation</i> , 2011, 124, e1-65.	1.2	262
42	Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2006, 24, 75-84.	0.3	253
43	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.	1.0	249
44	Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Guidelines). <i>Circulation</i> , 2011, 124, e1-65.	1.2	222
45	Insufficiency of PITX2 Leads to Atrial Electrical and Structural Remodeling Linked to Arrhythmogenesis. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 269-279.	5.1	221
46	Hypertension magnitude and management in the elderly population of Spain. <i>Journal of Hypertension</i> , 2002, 20, 2157-2164.	0.3	217
47	Vasodilator effects of quercetin in isolated rat vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1993, 239, 1-7.	1.7	185
48	Blood Pressure Control and Physician Management of Hypertension in Hospital Hypertension Units in Spain. <i>Hypertension</i> , 2004, 43, 1338-1344.	1.3	183
49	Stereoselective Block of Cardiac Sodium Channels by Bupivacaine in Guinea Pig Ventricular Myocytes. <i>Circulation</i> , 1995, 92, 3014-3024.	1.6	174
50	Endothelium-Independent Vasodilator Effects of the Flavonoid Quercetin and Its Methylated Metabolites in Rat Conductance and Resistance Arteries. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 66-72.	1.3	170
51	Serotonin Inhibits Voltage-Gated K ⁺ Currents in Pulmonary Artery Smooth Muscle Cells. <i>Circulation Research</i> , 2006, 98, 931-938.	2.0	170
52	Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 549-567.	0.8	166
53	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1064-1108.	1.2	154
54	Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. <i>Free Radical Biology and Medicine</i> , 2012, 52, 70-79.	1.3	154

#	ARTICLE	IF	CITATIONS
55	In Humans, Chronic Atrial Fibrillation Decreases the Transient Outward Current and Ultrarapid Component of the Delayed Rectifier Current Differentially on Each Atria and Increases the Slow Component of the Delayed Rectifier Current in Both. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2346-2354.	1.2	152
56	Thromboxane A ₂ -Induced Inhibition of Voltage-Gated K ⁺ Channels and Pulmonary Vasoconstriction. <i>Circulation Research</i> , 2003, 93, 656-663.	2.0	140
57	Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. <i>Europace</i> , 2011, 13, 161-173.	0.7	140
58	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1. <i>European Heart Journal</i> , 2015, 36, 2677-2680.	1.0	131
59	Novel therapeutic targets for the treatment of heart failure. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 536-555.	21.5	125
60	Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. <i>Journal of Hypertension</i> , 2002, 20, 1843-1854.	0.3	124
61	Cancer Chemotherapy and Cardiac Arrhythmias: A Review. <i>Drug Safety</i> , 2015, 38, 129-152.	1.4	118
62	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq0.0.0 rgBT /Overlock 1	0.3	114
63	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1 1 0.784314 rgBT /0	0.3	114
64	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	1.4	113
65	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 1015-1023.	1.0	109
66	Glucuronidated Quercetin Lowers Blood Pressure in Spontaneously Hypertensive Rats via Deconjugation. <i>PLoS ONE</i> , 2012, 7, e32673.	1.1	104
67	Drug-Induced Torsade de Pointes. From Molecular Biology to Bedside.. <i>The Japanese Journal of Pharmacology</i> , 2000, 83, 1-19.	1.2	102
68	Quercetin and Isorhamnetin Prevent Endothelial Dysfunction, Superoxide Production, and Overexpression of p47phox Induced by Angiotensin II in Rat Aorta. <i>Journal of Nutrition</i> , 2007, 137, 910-915.	1.3	98
69	Nitric Oxide (NO) Scavenging and NO Protecting Effects of Quercetin and Their Biological Significance in Vascular Smooth Muscle. <i>Molecular Pharmacology</i> , 2004, 65, 851-859.	1.0	89
70	Effects of Losartan on Blood Pressure, Metabolic Alterations, and Vascular Reactivity in the Fructose-Induced Hypertensive Rat. <i>Hypertension</i> , 1995, 26, 1074-1078.	1.3	87
71	Cardiac electrophysiological effects of nitric oxide. <i>Cardiovascular Research</i> , 2010, 87, 593-600.	1.8	86
72	Class III Antiarrhythmic Effects of Zatebradine. <i>Circulation</i> , 1996, 94, 562-570.	1.6	86

#	ARTICLE	IF	CITATIONS
73	Chronic Atrial Fibrillation Increases MicroRNA-21 in Human Atrial Myocytes Decreasing L-Type Calcium Current. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 861-868.	2.1	83
74	Antihypertensive Effects of Peroxisome Proliferator-Activated Receptor- β Activation in Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2011, 58, 733-743.	1.3	80
75	The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H ₂ O ₂ . Role in vasodilatation. <i>Cardiovascular Research</i> , 2007, 73, 424-431.	1.8	77
76	Nav1.5 N-terminal domain binding to β 1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels. <i>Cardiovascular Research</i> , 2016, 110, 279-290.	1.8	77
77	Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15631-15636.	3.3	75
78	Effects of chronic quercetin treatment on hepatic oxidative status of spontaneously hypertensive rats. <i>Molecular and Cellular Biochemistry</i> , 2001, 221, 155-160.	1.4	74
79	Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. <i>Cardiovascular Research</i> , 2006, 72, 80-89.	1.8	74
80	Losartan and Its Metabolite E3174 Modify Cardiac Delayed Rectifier K ⁺ Currents. <i>Circulation</i> , 2000, 101, 1199-1205.	1.6	71
81	Molecular Determinants of Stereoselective Bupivacaine Block of hKv1.5 Channels. <i>Circulation Research</i> , 1997, 81, 1053-1064.	2.0	70
82	I _{Kur} /Kv1.5 channel blockers for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 399-416.	1.9	69
83	Effects of Irbesartan on Cloned Potassium Channels Involved in Human Cardiac Repolarization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 862-873.	1.3	66
84	Spironolactone and Its Main Metabolite, Canrenoic Acid, Block Human Ether-a-Go-Go-Related Gene Channels. <i>Circulation</i> , 2003, 107, 889-895.	1.6	65
85	Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 527-547.	0.9	62
86	Nitric Oxide Increases Cardiac I _{K1} by Nitrosylation of Cysteine 76 of Kir2.1 Channels. <i>Circulation Research</i> , 2009, 105, 383-392.	2.0	61
87	Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing I _{Ks} and decreasing I _{Ca,L} . <i>Cardiovascular Research</i> , 2016, 109, 431-441.	1.8	59
88	Role of Reactive Oxygen Species in Kv Channel Inhibition and Vasoconstriction Induced by TP Receptor Activation in Rat Pulmonary Arteries. <i>Annals of the New York Academy of Sciences</i> , 2006, 1091, 41-51.	1.8	57
89	Activation of peroxisome proliferator-activated receptor- β (PPAR β) prevents endothelial dysfunction in type 1 diabetic rats. <i>Free Radical Biology and Medicine</i> , 2012, 53, 730-741.	1.3	57
90	Chronic atrial fibrillation up-regulates β 1-Adrenoceptors affecting repolarizing currents and action potential duration. <i>Cardiovascular Research</i> , 2013, 97, 379-388.	1.8	57

#	ARTICLE	IF	CITATIONS
91	Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. <i>Cardiovascular Research</i> , 1997, 35, 341-350.	1.8	56
92	An update on atrial fibrillation in 2014: From pathophysiology to treatment. <i>International Journal of Cardiology</i> , 2016, 203, 22-29.	0.8	56
93	Increased NADPH oxidase activity mediates spontaneous aortic tone in genetically hypertensive rats. <i>European Journal of Pharmacology</i> , 2006, 544, 97-103.	1.7	55
94	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 60</i>	1.0	55
95	Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. <i>European Journal of Pharmacology</i> , 1985, 108, 121-131.	1.7	54
96	Structural Determinants of Potency and Stereoselective Block of hKv1.5 Channels Induced by Local Anesthetics. <i>Molecular Pharmacology</i> , 1998, 54, 162-169.	1.0	54
97	Cardiovascular Effects of Isorhamnetin and Quercetin in Isolated Rat and Porcine Vascular Smooth Muscle and Isolated Rat Atria. <i>Planta Medica</i> , 2002, 68, 307-310.	0.7	54
98	Antihypertensive Efficacy and Tolerability of Lercanidipine in Daily Clinical Practice. The ELYPSE Study. <i>Blood Pressure</i> , 2002, 11, 95-100.	0.7	54
99	Relaxant Effects of Carbon Monoxide Compared with Nitric Oxide in Pulmonary and Systemic Vessels of Newborn Piglets. <i>Pediatric Research</i> , 2000, 48, 546-553.	1.1	53
100	Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. <i>British Journal of Pharmacology</i> , 1998, 125, 969-978.	2.7	51
101	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 605-621.	0.9	51
102	Vasorelaxant Effects of the Bioflavonoid Chrysin in Isolated Rat Aorta. <i>Planta Medica</i> , 2001, 67, 567-569.	0.7	50
103	Effects of the Flavonoid Quercetin and its Methylated Metabolite Isorhamnetin in Isolated Arteries from Spontaneously Hypertensive Rats. <i>Planta Medica</i> , 2003, 69, 995-1000.	0.7	50
104	Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. <i>Cardiovascular Research</i> , 2010, 85, 56-67.	1.8	48
105	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	1.0	48
106	Propafenone Preferentially Blocks the Rapidly Activating Component of Delayed Rectifier K + Current in Guinea Pig Ventricular Myocytes. <i>Circulation Research</i> , 1995, 76, 223-235.	2.0	47
107	Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block. <i>British Journal of Pharmacology</i> , 2002, 137, 1269-1279.	2.7	46
108	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	1.4	46

#	ARTICLE	IF	CITATIONS
109	Effects of atorvastatin and simvastatin on atrial plateau currents. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 42, 931-945.	0.9	45
110	Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. <i>European Cardiology Review</i> , 2019, 14, 23-32.	0.7	44
111	Vasodilator effects of visnagin in isolated rat vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1995, 286, 115-122.	1.7	43
112	Effects of Ropivacaine on a Potassium Channel (hKv1.5) Cloned from Human Ventricle. <i>Anesthesiology</i> , 1997, 86, 718-728.	1.3	43
113	p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient. <i>Heart Rhythm</i> , 2013, 10, 264-272.	0.3	42
114	ELECTROPHYSIOLOGICAL EFFECTS OF IMPRAMINE ON BOVINE VENTRICULAR MUSCLE AND PURKINJE FIBRES. <i>British Journal of Pharmacology</i> , 1980, 70, 15-23.	2.7	41
115	Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1). <i>Cardiovascular Research</i> , 2008, 80, 375-384.	1.8	41
116	Cardiovascular Effects of Flavonoids. <i>Current Medicinal Chemistry</i> , 2019, 26, 6991-7034.	1.2	41
117	Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current. <i>Cardiovascular Research</i> , 2004, 62, 86-95.	1.8	40
118	Proteomic Study of Plasma from Moderate Hypercholesterolemic Patients. <i>Journal of Proteome Research</i> , 2006, 5, 2301-2308.	1.8	40
119	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal Supplements</i> , 2007, 9, C3-C74.	0.0	40
120	Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. , 2007, 114, 107-126.		40
121	Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. <i>Proteomics</i> , 2011, 11, 3335-3348.	1.3	40
122	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	1.0	40
123	Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7250-E7259.	3.3	39
124	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
125	μ - and δ -opioid receptor-mediated contractile effects on rat aortic vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1995, 277, 99-105.	1.7	38
126	Assembly with the Kv ^{1.3} Subunit Modulates Drug Block of hKv1.5 Channels. <i>Molecular Pharmacology</i> , 2002, 62, 1456-1463.	1.0	38

#	ARTICLE	IF	CITATIONS
127	Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). <i>Cardiovascular Research</i> , 2002, 56, 104-117.	1.8	38
128	Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase. <i>Clinical Science</i> , 2011, 120, 321-333.	1.8	38
129	Tbx20 controls the expression of the <i>KCNH2</i> gene and of hERG channels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E416-E425.	3.3	38
130	Brugada syndrome trafficking defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels. <i>JCI Insight</i> , 2018, 3, .	2.3	37
131	Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 155-161.	4.0	36
132	Functional expression of an inactivating potassium channel (Kv4.3) in a mammalian cell line. <i>Cardiovascular Research</i> , 1999, 41, 212-219.	1.8	35
133	Postnatal maturational shift from PKC β and voltage-gated K channels to RhoA/Rho kinase in pulmonary vasoconstriction. <i>Cardiovascular Research</i> , 2005, 66, 84-93.	1.8	35
134	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 108-118.	1.4	35
135	Kir2.1-Nav1.5 Channel Complexes Are Differently Regulated than Kir2.1 and Nav1.5 Channels Alone. <i>Frontiers in Physiology</i> , 2017, 8, 903.	1.3	35
136	Direct Effects of Candesartan and Eprosartan on Human Cloned Potassium Channels Involved in Cardiac Repolarization. <i>Molecular Pharmacology</i> , 2001, 59, 825-836.	1.0	34
137	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. <i>International Journal of Cardiology</i> , 2015, 201, S15-S23.	0.8	32
138	Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1991, 344, 645-52.	1.4	31
139	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 226-236.	1.4	31
140	Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. <i>European Journal of Pharmacology</i> , 2010, 627, 242-250.	1.7	30
141	Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 201-210.	0.9	30
142	Management of stable angina: A commentary on the European Society of Cardiology guidelines. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1401-1412.	0.8	30
143	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 200-205.	1.4	30
144	Effects of imipramine on the transient outward current in rabbit atrial single cells. <i>British Journal of Pharmacology</i> , 1992, 106, 464-469.	2.7	29

#	ARTICLE	IF	CITATIONS
145	Postnatal Maturation of Phosphodiesterase 5 (PDE5) in Piglet Pulmonary Arteries: Activity, Expression, Effects of PDE5 Inhibitors, and Role of the Nitric Oxide/Cyclic GMP Pathway. <i>Pediatric Research</i> , 2004, 56, 563-570.	1.1	29
146	Vascular superoxide production by endothelin-1 requires Src non-receptor protein tyrosine kinase and MAPK activation. <i>Atherosclerosis</i> , 2010, 212, 78-85.	0.4	29
147	Safety of Flecainide. <i>Drug Safety</i> , 2012, 35, 273-289.	1.4	29
148	Group B <i>Streptococcus</i> and <i>E. coli</i> LPS-induced NO-dependent hyporesponsiveness to noradrenaline in isolated intrapulmonary arteries of neonatal piglets. <i>British Journal of Pharmacology</i> , 1995, 115, 261-266.	2.7	28
149	Effects of the two enantiomers, S–6257 and S–6260, of a new bradycardic agent on guinea pig isolated cardiac preparations. <i>British Journal of Pharmacology</i> , 1995, 115, 787-794.	2.7	28
150	Effects of Visnadine on Rat Isolated Vascular Smooth Muscles. <i>Planta Medica</i> , 1997, 63, 233-236.	0.7	28
151	Involvement of thromboxane A2 in the endothelium-dependent contractions induced by myricetin in rat isolated aorta. <i>British Journal of Pharmacology</i> , 1999, 127, 1539-1544.	2.7	28
152	Mechanisms involved in SNP-induced relaxation and [Ca ²⁺] _i reduction in piglet pulmonary and systemic arteries. <i>British Journal of Pharmacology</i> , 2001, 132, 959-967.	2.7	28
153	Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations. <i>Cardiovascular Research</i> , 2004, 64, 457-466.	1.8	28
154	Comparative Expression of Proteins in Left and Right Atrial Appendages From Patients With Mitral Valve Disease at Sinus Rhythm and Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 859-868.	0.8	28
155	Comparison of Agents That Affect Aldosterone Action. <i>Seminars in Nephrology</i> , 2014, 34, 285-306.	0.6	28
156	Electrophysiological Effects of 5-Hydroxypropafenone on Guinea Pig Ventricular Muscle Fibres. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 10, 523-529.	0.8	27
157	Inhibitory effects of quercetin and staurosporine on phasic contractions in rat vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1994, 262, 149-156.	1.7	27
158	Role of K ⁺ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways. <i>British Journal of Pharmacology</i> , 1998, 123, 847-854.	2.7	27
159	Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. <i>British Journal of Pharmacology</i> , 1999, 128, 1071-1081.	2.7	27
160	Blockade of Cardiac Potassium and Other Channels by Antihistamines. <i>Drug Safety</i> , 1999, 21, 11-18.	1.4	27
161	Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore. <i>Biochemical Pharmacology</i> , 2013, 86, 267-278.	2.0	27
162	Unresolved issues in the management of chronic stable angina. <i>International Journal of Cardiology</i> , 2015, 201, 200-207.	0.8	27

#	ARTICLE	IF	CITATIONS
163	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	1.4	27
164	Ventricular tachycardia in a patient with congenital coronary arteriovenous fistula. <i>American Heart Journal</i> , 1992, 124, 503-505.	1.2	26
165	Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: Sâ€16257â€2 and Sâ€16260â€2. <i>British Journal of Pharmacology</i> , 1996, 117, 1293-1301.	2.7	26
166	Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. <i>British Journal of Pharmacology</i> , 2005, 146, 146-161.	2.7	26
167	Future drug discovery in renin-angiotensin-aldosterone system intervention. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-22.	2.5	26
168	A comparison of Josamycin with macrolides and related antibiotics on isolated rat atria. <i>European Journal of Pharmacology</i> , 1982, 80, 285-293.	1.7	25
169	Effect of milrinone on contractility and ⁴⁵ Ca movements in the isolated rabbit aorta. <i>European Journal of Pharmacology</i> , 1988, 148, 239-246.	1.7	25
170	Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. <i>Cardiovascular Research</i> , 2003, 57, 660-669.	1.8	25
171	Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1300-1312.	0.8	25
172	The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 946-958.	0.8	25
173	Role of UCP2 in the protective effects of PPAR α activation on lipopolysaccharide-induced endothelial dysfunction. <i>Biochemical Pharmacology</i> , 2016, 110-111, 25-36.	2.0	25
174	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 104-114.	1.4	25
175	Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A ₂ -mimetic U46619. <i>British Journal of Pharmacology</i> , 1997, 121, 1323-1333.	2.7	24
176	Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. <i>British Journal of Pharmacology</i> , 2003, 138, 1475-1484.	2.7	24
177	Association of 14-3-3 Proteins to β 1-Adrenergic Receptors Modulates Kv11.1 K ⁺ Channel Activity in Recombinant Systems. <i>Molecular Biology of the Cell</i> , 2006, 17, 4666-4674.	0.9	24
178	Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. <i>Cardiovascular Research</i> , 2014, 104, 337-346.	1.8	24
179	Effect of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase. <i>European Journal of Pharmacology</i> , 1997, 338, 25-33.	1.7	23
180	Nitric oxide- and nitric oxide donors-induced relaxation and its modulation by oxidative stress in piglet pulmonary arteries. <i>British Journal of Pharmacology</i> , 2001, 133, 615-624.	2.7	23

#	ARTICLE	IF	CITATIONS
181	Pharmacological Approaches in the Treatment of Atrial Fibrillation. <i>Current Medicinal Chemistry</i> , 2004, 11, 13-28.	1.2	23
182	Effects of MiRP1 and DPP6 β -subunits on the blockade induced by flecainide of $K_{v4.3}/K_{ChIP2}$ channels. <i>British Journal of Pharmacology</i> , 2008, 154, 774-786.	2.7	23
183	Effects of peroxisome proliferator-activated receptor- β activation in endothelin-dependent hypertension. <i>Cardiovascular Research</i> , 2013, 99, 622-631.	1.8	23
184	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
185	Electrophysiological effects of desipramine of guinea pig papillary muscles. <i>European Journal of Pharmacology</i> , 1979, 55, 171-179.	1.7	22
186	Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 288, L125-L130.	1.3	22
187	Drug-induced atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 615-634.	1.0	22
188	New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 99-119.	1.3	22
189	Estratificaci3n, monitorizaci3n y control del riesgo cardiovascular en pacientes con c3ncer. Documento de consenso de SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC y AECC. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 438-448.	0.6	22
190	New insights in the pharmacological therapy of arterial hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 423-427.	1.0	21
191	New Antihypertensive Drugs Under Development. <i>Current Medicinal Chemistry</i> , 2014, 22, 305-342.	1.2	21
192	THE MECHANISM OF THE POSITIVE INOTROPIC ACTION OF KETAMINE ON ISOLATED ATRIA OF THE RAT. <i>British Journal of Pharmacology</i> , 1982, 76, 85-93.	2.7	20
193	Effects of Visnagin on Cyclic Nucleotide Phosphodiesterases and Their Role in its Inhibitory Effects on Vascular Smooth Muscle Contraction. <i>General Pharmacology</i> , 1999, 32, 71-74.	0.7	20
194	Benefits of Emergency Departments'™ Contribution to Stroke Prophylaxis in Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 1344-1352.	1.0	20
195	Tonic and Phasic Vmax Block Induced by 5-Hydroxypropafenone in Guinea Pig Ventricular Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 1988, 12, 423-431.	0.8	19
196	Role of Protein Kinase C α and Its Adaptor Protein p62 in Voltage-Gated Potassium Channel Modulation in Pulmonary Arteries. <i>Molecular Pharmacology</i> , 2007, 72, 1301-1309.	1.0	19
197	Tonic and Frequency-Dependent Vmax Block Induced by Imipramine in Guinea Pig Ventricular Muscle Fibers. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 15, 414-420.	0.8	18
198	Comparative effects of non-sedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels. <i>European Journal of Pharmacology</i> , 1997, 326, 257-263.	1.7	18

#	ARTICLE	IF	CITATIONS
199	Effects of Several Class I Antiarrhythmic Drugs on Isolated Rat Aortic Vascular Smooth Muscle. <i>General Pharmacology</i> , 1997, 29, 539-543.	0.7	18
200	Functional Characterization of a Novel Frameshift Mutation in the C-terminus of the Nav1.5 Channel Underlying a Brugada Syndrome with Variable Expression in a Spanish Family. <i>PLoS ONE</i> , 2013, 8, e81493.	1.1	18
201	Electrophysiological effects of propafenone on isolated guinea-pig ventricular muscle and sheep purkinje fibres. <i>European Journal of Pharmacology</i> , 1985, 118, 331-340.	1.7	17
202	Effects of flecainide on isolated vascular smooth muscles of rat. <i>British Journal of Pharmacology</i> , 1991, 104, 726-730.	2.7	17
203	Investigational Positive Inotropic Agents for Acute Heart Failure. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009, 9, 193-205.	0.2	17
204	Old and New Molecular Mechanisms Associated with Platelet Resistance to Antithrombotics. <i>Pharmaceutical Research</i> , 2010, 27, 2365-2373.	1.7	17
205	Effects of khellin on contractile responses and $^{45}\text{Ca}^{2+}$ movements in rat isolated aorta. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 43, 46-48.	1.2	17
206	Renin-angiotensin system blockade: Finerenone. <i>Nephrologie Et Therapeutique</i> , 2017, 13, S47-S53.	0.2	17
207	Vascular Selectivity of Seven Prototype Calcium Antagonists. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 768-775.	0.8	16
208	Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5. <i>British Journal of Pharmacology</i> , 1997, 122, 796-798.	2.7	16
209	Benzocaine enhances and inhibits the K^{+} current through a human cardiac cloned channel (Kv1.5). <i>Cardiovascular Research</i> , 1999, 42, 510-520.	1.8	16
210	Cytosolic Ca^{2+} and Phosphoinositide Hydrolysis Linked to Constitutively Active β_1 -Adrenoceptors in Vascular Smooth Muscle. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1006-1014.	1.3	16
211	The safety of digoxin as a pharmacological treatment of atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 453-467.	1.0	16
212	Vascular and Central Activation of Peroxisome Proliferator-Activated Receptor- α Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 151-163.	1.3	16
213	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018, 39, 2274-2281.	1.0	16
214	Effects of Group B Streptococcus on the Responses to U46619, Endothelin-1, and Noradrenaline in Isolated Pulmonary and Mesenteric Arteries of Piglets. <i>Pediatric Research</i> , 1996, 40, 827-833.	1.1	16
215	Genetically engineered mice as a model for studying cardiac arrhythmias. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 22.	3.0	16
216	Electrophysiologic Interactions Between Mexiletine and Propafenone in Guinea Pig Papillary Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, 351-357.	0.8	15

#	ARTICLE	IF	CITATIONS
217	Effects of Antihypertensive Drugs on Blood Pressure and Metabolic Alterations in the Fructose-Induced Hypertensive Rat. <i>American Journal of Hypertension</i> , 1996, 9, 669-674.	1.0	15
218	Lack of Endotoxin-Induced Hyporesponsiveness to U46619 in Isolated Neonatal Porcine Pulmonary but Not Mesenteric Arteries. <i>Journal of Vascular Research</i> , 1996, 33, 249-257.	0.6	15
219	Effects of nicorandil as compared to mixtures of sodium nitroprusside and levromakalim in isolated rat aorta. <i>British Journal of Pharmacology</i> , 1999, 126, 1025-1033.	2.7	15
220	Investigational calcium channel blockers for the treatment of hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1295-1309.	1.9	15
221	New drugs in preclinical and early stage clinical development in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 51-71.	1.9	15
222	Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome. <i>Cardiovascular Research</i> , 2022, 118, 1046-1060.	1.8	15
223	Drug-Induced Torsade de Pointes: From Molecular Biology to Bedside. <i>The Japanese Journal of Pharmacology</i> , 2000, 83, 1-19.	1.2	15
224	Vasodilator effects of sodium nitroprusside, levromakalim and their combination in isolated rat aorta. <i>British Journal of Pharmacology</i> , 1999, 128, 1419-1426.	2.7	14
225	Flavonoids and cardiovascular diseases. <i>Studies in Natural Products Chemistry</i> , 2001, 25, 565-605.	0.8	14
226	The Renin-Angiotensin System and Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2015, 13, 125-148.	1.3	14
227	Sex-related differences in the pharmacological treatment of heart failure. , 2022, 229, 107891.		14
228	Effects of propafenone on ⁴⁵ Ca movements and contractile responses in vascular smooth muscle. <i>British Journal of Pharmacology</i> , 1991, 103, 1453-1457.	2.7	13
229	Effects of (S)-nafedone, a new antidepressant, in isolated guinea-pig atrial and ventricular muscle fibres. <i>European Journal of Pharmacology</i> , 1991, 199, 43-50.	1.7	13
230	New Investigational Drugs for the Management of Acute Heart Failure Syndromes. <i>Current Medicinal Chemistry</i> , 2010, 17, 363-390.	1.2	13
231	Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. <i>European Heart Journal</i> , 2020, 41, 2067-2069.	1.0	13
232	Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 283, L839-L848.	1.3	13
233	Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1039-47.	2.3	13
234	Effects of (S)-nafedone on ⁴⁵ Ca ²⁺ fluxes and contractions in rat isolated vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1993, 232, 105-111.	1.7	12

#	ARTICLE	IF	CITATIONS
235	Electrophysiological Effects of the Combination of Imipramine and Desipramine in Guinea Pig Papillary Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 21, 13-20.	0.8	12
236	Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine. <i>British Journal of Pharmacology</i> , 1994, 113, 1281-1288.	2.7	12
237	Cardiovascular Effects of the Novel Potassium Channel Opener UR-8225. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 295-305.	0.8	12
238	Electromechanical Effects of Zatebradine on Isolated Guinea Pig Cardiac Preparations. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 46-54.	0.8	12
239	Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. <i>Revista Espanola De Cardiología</i> , 2004, 57, 447-464.	0.6	12
240	Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke. <i>Journal of Neurochemistry</i> , 2012, 121, 314-325.	2.1	12
241	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. <i>Hypertension</i> , 2019, 74, 130-136.	1.3	12
242	Electrophysiological effects of bunaphtine on isolated rat atria. <i>European Journal of Pharmacology</i> , 1980, 62, 81-88.	1.7	11
243	Effect of somatostatin on ⁴⁵ Ca fluxes in guinea pig isolated atria. <i>British Journal of Pharmacology</i> , 1987, 90, 309-314.	2.7	11
244	Electrophysiological effects of E-3753, a new antiarrhythmic drug, in guinea pig ventricular muscle. <i>British Journal of Pharmacology</i> , 1989, 96, 970-976.	2.7	11
245	Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels. <i>European Journal of Pharmacology</i> , 1992, 219, 279-284.	1.7	11
246	Drug-induced atrial fibrillation: does it matter?. <i>Discovery Medicine</i> , 2012, 14, 295-9.	0.5	11
247	Evidence of abnormal automaticity and triggering activity in incessant ectopic atrial tachycardia. <i>American Heart Journal</i> , 1988, 116, 550-552.	1.2	10
248	Effects of Oleuropeoside in Isolated Guinea-Pig Atria. <i>Planta Medica</i> , 1993, 59, 318-322.	0.7	10
249	Corrigendum to 'ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial)' <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.7	10
250	Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome. <i>Heart Rhythm</i> , 2011, 8, 463-470.	0.3	10
251	Ranolazine: an antianginal drug with antiarrhythmic properties. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 815-827.	0.6	10
252	Platelet Content of Nitric Oxide Synthase 3 Phosphorylated At Serine1177 Is Associated with the Functional Response of Platelets to Aspirin. <i>PLoS ONE</i> , 2013, 8, e82574.	1.1	10

#	ARTICLE	IF	CITATIONS
253	Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 98-112.	0.9	10
254	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	1.4	10
255	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 557-567.	1.4	10
256	New therapeutic targets for the development of positive inotropic agents. <i>Discovery Medicine</i> , 2011, 12, 381-92.	0.5	10
257	Mechanisms by which calcium modulates diastolic depolarization in sheep cardiac Purkinje fibers. <i>Journal of Electrocardiology</i> , 1991, 24, 349-361.	0.4	9
258	Effects of Oxodipine and Nitrendipine on the Size of Experimental Myocardial Infarct in the Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 74, 321-329.	0.0	9
259	Class I and III antiarrhythmic actions of prazosin in guinea pig papillary muscles. <i>British Journal of Pharmacology</i> , 1994, 111, 717-722.	2.7	9
260	Stereoselective effects of the enantiomers, quinidine and quinine, on depolarization- and agonist-mediated responses in rat isolated aorta. <i>British Journal of Pharmacology</i> , 1996, 117, 105-110.	2.7	9
261	Estudio farmacodinámico del policomprimido cardiovascular: ¿existe algún tipo de interacción entre los monocomponentes?. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 51-58.	0.6	9
262	Zfhx3 Transcription Factor Represses the Expression of SCN5A Gene and Decreases Sodium Current Density (INa). <i>International Journal of Molecular Sciences</i> , 2021, 22, 13031.	1.8	9
263	Pulmonary Artery Vasoconstriction but not [Ca ²⁺] _i Signal Stimulated by Thromboxane A ₂ Is Partially Resistant to NO. <i>Pediatric Research</i> , 2001, 50, 508-514.	1.1	8
264	Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. <i>International Journal of Cardiology</i> , 2017, 233, 1-11.	0.8	8
265	Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. <i>Future Cardiology</i> , 2022, 18, 235-251.	0.5	8
266	New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors – hype or hope?. <i>Discovery Medicine</i> , 2014, 18, 249-54.	0.5	8
267	Pharmacotherapy for hypertension in pregnant patients: special considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 963-982.	0.9	7
268	The p.P888L SAP97 polymorphism increases the transient outward current (I _{to,f}) and abbreviates the action potential duration and the QT interval. <i>Scientific Reports</i> , 2020, 10, 10707.	1.6	7
269	Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 277-279.	1.4	7
270	Effects of bunaphtine on ⁴⁵ Ca movements in rat aortic smooth muscle. <i>Experientia</i> , 1983, 39, 761-763.	1.2	6

#	ARTICLE	IF	CITATIONS
271	Electrophysiological effects of the combination of mexiletine and flecainide in guinea-pig ventricular fibres. <i>British Journal of Pharmacology</i> , 1991, 103, 1411-1416.	2.7	6
272	Effects of aminophylline on contractions and ⁴⁵ Ca uptake in isolated rat vascular smooth muscle. <i>General Pharmacology</i> , 1992, 23, 601-606.	0.7	6
273	Pulmonary versus systemic effects of vasodilator drugs: an in vitro study in isolated intrapulmonary and mesenteric arteries of neonatal piglets. <i>European Journal of Pharmacology</i> , 1996, 314, 91-98.	1.7	6
274	Endothelium-Derived Nitric Oxide-Dependent Response to Hypoxia in Piglet Intrapulmonary Arteries. <i>Neonatology</i> , 1997, 72, 62-70.	0.9	6
275	TGF β 3 mutations cause arrhythmogenic right ventricular dysplasia type 1 and open the door to understanding the biological role of TGF β 3 (where there's a will, there's a way): EXPERT'S PERSPECTIVE. <i>Cardiovascular Research</i> , 2012, 96, 188-190.	1.8	6
276	New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 193-194.	1.4	6
277	Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AECC, and AECC. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 438-448.	0.4	6
278	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	6
279	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	0.8	6
280	Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity. <i>Drug Safety</i> , 2022, 45, 101-126.	1.4	6
281	Effect of oxodipine and nifedipine on guinea-pig ileum. <i>General Pharmacology</i> , 1988, 19, 771-774.	0.7	5
282	Effects of lisinopril on cardiac contractility and ionic currents. <i>General Pharmacology</i> , 1994, 25, 825-832.	0.7	5
283	Modulation of arterial Na ⁺ -K ⁺ -ATPase-induced [Ca ²⁺] _i reduction and relaxation by norepinephrine, ET-1, and PMA. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H651-H657.	1.5	5
284	Aldosterone a Relevant Factor in the Beginning and Evolution of Arterial Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 468-469.	1.0	5
285	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	1.4	5
286	Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 51-58.	0.4	5
287	Dronedarone. <i>Drugs of Today</i> , 2011, 47, 109.	0.7	5
288	Interaction of cocaine and bunaphtide on the 3H-norepinephrine uptake mechanism on isolated left atrium of guinea-pig. <i>Experientia</i> , 1978, 34, 770-770.	1.2	4

#	ARTICLE	IF	CITATIONS
289	Effects of pinacainide on contractile responses and ^{45}Ca movements in rat isolated vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1985, 111, 227-233.	1.7	4
290	Electrophysiological effects of CRE ϵ 1087 in guinea-pig ventricular muscles. <i>British Journal of Pharmacology</i> , 1992, 107, 515-520.	2.7	4
291	Effects of lisinopril on electromechanical properties and membrane currents in guinea-pig cardiac preparations. <i>British Journal of Pharmacology</i> , 1993, 109, 873-879.	2.7	4
292	Propafenone Slows Conduction and Produces a Nonuniform Recovery of Excitability Between Purkinje and Ventricular Muscle Fibers. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 203-207.	0.8	4
293	Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles. <i>British Journal of Pharmacology</i> , 1997, 120, 187-192.	2.7	4
294	Relaxant Effects of the Soluble Guanylate Cyclase Activator and NO Sensitizer YC-1 in Piglet Pulmonary Arteries. <i>Neonatology</i> , 2006, 90, 66-72.	0.9	4
295	Digenic Heterozygosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 324-332.	0.4	4
296	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 100-103.	1.4	4
297	Vasoconstrictor and Vasodilator Effects of Disopyramide on Isolated Rat Vascular Smooth Muscle. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, 745-752.	0.8	4
298	Comparison of three \hat{I}^2 -amino anilides: IQB-M-81, lidocaine and tocainide, on isolated rat atria. <i>European Journal of Pharmacology</i> , 1983, 95, 93-99.	1.7	3
299	Low quality of some generic cardiovascular medicinal products represents a matter for growing concern. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 176-187.	1.4	3
300	Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 234-236.	2.3	3
301	Factors associated with poor prognosis in patients with atrial fibrillation: An emergency department perspective the EMERG-AF study. <i>American Journal of Emergency Medicine</i> , 2021, 50, 270-277.	0.7	3
302	An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	1.3	3
303	Tonic and frequency-dependent V_{max} block induced by (S)-nafnodone, a new antidepressant drug, in guinea-pig papillary muscles. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1991, 343, 638-44.	1.4	2
304	Rationale and Clinical Evidence for the Effects of New Pharmacological Treatments for Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 447-464.	0.4	2
305	Características farmacológicas de los ARA-II. ¿Son todos iguales?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 10C-24C.	0.2	2
306	A comparison of the effects of oxodipine and nifedipine on rat vas deferens. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 40, 657-659.	1.2	2

#	ARTICLE	IF	CITATIONS
307	Edoxabán. Propiedades farmacocinéticas y farmacodinámicas. Revista Espanola De Cardiologia Suplementos, 2016, 16, 60-66.	0.2	2
308	Pharmacological Bases of Antiarrhythmic Therapy. , 2018, , 513-524.		2
309	Happy 50th anniversary of amiodarone (1969–2019). International Journal of Cardiology, 2019, 293, 115-116.	0.8	2
310	ISCHEMIA Trial: Key Questions and Answers. European Cardiology Review, 2021, 16, e34.	0.7	2
311	Treatment of Coronavirus Disease 2019: Shooting in the Dark. European Cardiology Review, 2020, 15, e59.	0.7	2
312	Pharmacology of CRE-1087, A New Antiarrhythmic Drug. Cardiovascular Drug Reviews, 1992, 10, 307-322.	4.4	1
313	Aminophylline preferentially inhibits chloroethylclonidine-insensitive $\hat{\alpha}$ -adrenoceptor-mediated contractions in rat aorta. General Pharmacology, 1993, 24, 1359-1364.	0.7	1
314	Pharmacology of UR-8225, a New Potassium Channel Opener. Cardiovascular Drug Reviews, 1996, 14, 256-271.	4.4	1
315	Farmacología de los ácidos grasos omega-3. Revista Espanola De Cardiologia Suplementos, 2006, 6, 3D-19D.	0.2	1
316	Mecanismo de acción de la eplerenona. Revista Espanola De Cardiologia Suplementos, 2006, 6, 31B-47B.	0.2	1
317	The HERACLES Cardiovascular Network. Revista Espanola De Cardiologia (English Ed), 2008, 61, 66-75.	0.4	1
318	Vagal Stimulation and Atrial Electrical Remodeling. Revista Espanola De Cardiologia (English Ed), 2009, 62, 729-732.	0.4	1
319	Pharmacologic Bases of Antiarrhythmic Therapy. , 2014, , 529-540.		1
320	After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 3-5.	1.4	1
321	Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 425-437.	1.0	1
322	Cardiovascular Medications. , 2021, , 597-642.		1
323	Does anticoagulation reduce mortality in patients with atrial fibrillation who later developed a COVID-19 infection?. International Journal of Cardiology, 2021, 331, 340-341.	0.8	1
324	Fluoroquinolone use and valvular heart disease: is the jury still out?. European Heart Journal, 2021, 42, 2909-2911.	1.0	1

#	ARTICLE	IF	CITATIONS
325	Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have) Tj ETQq1 1 0.784314 rgBT /Overlo	1.3	1
326	Omecamtiv mecarbil cardiac myosin activator treatment of heart failure. Drugs of the Future, 2009, 34, 950.	0.0	1
327	Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1480-1486.	0.6	1
328	New Antianginal Drugs Still Not Available for Clinical Use. , 2015, , 189-234.		0
329	Selecting emergency therapy for patients with pre-eclampsia. Expert Opinion on Pharmacotherapy, 2020, 21, 1119-1122.	0.9	0
330	The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. Expert Opinion on Pharmacotherapy, 2021, 22, 1319-1341.	0.9	0
331	Class III Antiarrhythmic Drugs. , 2020, , 107-180.		0
332	Association between acute heart failure and major cardiovascular events in atrial fibrillation patients presenting at the emergency department: an EMERG-AF ancillary study. European Journal of Emergency Medicine, 2021, 28, 210-217.	0.5	0